ibrutinib,rituximab
abbvie,janssen
['lymsm']
3y ffs superior w/ asct + ibr vs asct (88 v 72%) and similar w/ asct + ibr vs ibr alone w/o asct. 3 yr os 92% in ibr arm w/o asct. slightly more heme tox w/ ibr + chemo (v chemo). #ash22 #lymsm 2/2
Leukemia/cell therapy doc & AYA Leukemia Program Leader at @MSKCancerCenter w/ special interest in ALL. Indie rock & Boston sports fan. Opinions=my own.??????